Artificial intelligence (AI) touches many aspects of both our professional and personal lives. One of the earliest recognitions of AI dates back more than 75 years to when Alan Turing, an English mathematician and computer scientist, pondered the question, “Can machines think?” Today, the answer seems closer to…
Inhaled IPF therapy LTI-03 awarded orphan drug status in Europe
On New Year’s Day, my daughters and I created vision boards for 2026. If you haven’t made one before, a vision board is a collage of images, quotes, and art that captures your goals and intentions for the year. We spent about an hour cutting pictures from old magazines and…
Treatment with the experimental oral therapy GRI-0621 modulated immune cell activity in adults with idiopathic pulmonary fibrosis (IPF) in an early Phase 2a clinical trial, according to new data announced by its developer, Gri Bio. Data from the Phase 2a study (NCT06331624) broadly suggest that GRI-0621 is…
If you’re a regular reader of my column, you’ve likely heard me say before that transplant patients commit to a lifetime of medical surveillance. I was diagnosed with idiopathic pulmonary fibrosis (IPF) on the last day of January in 2017. Until then, I didn’t see my primary care…
Over the holidays, for the first time in a long while, my home was full of voices, laughter, movement, and the comfort of family. I hosted the gathering, something I hadn’t been able to do in years. For someone like me living with pulmonary fibrosis, hosting a holiday party…
Individuals with lingering signs of pulmonary fibrosis (PF) months after recovering from COVID-19 were found to be older and to have significantly lower levels than normal of beneficial gut bacteria, particularly Bifidobacterium and Blautia, a new study reports. In follow-up experiments, a mouse model of PF given supplements of…
When I was diagnosed with idiopathic pulmonary fibrosis (IPF) in the early days of 2017, it seemed like my world moved in slow motion. Just a few months earlier, as my diagnostic journey began in the fall of 2016, my doctors sensed something was wrong, but no one could…
I had the opportunity to get away for a couple of days recently and went to the shore. As I looked out at the vastness of the ocean in the late afternoon sunlight, it occurred to me that this is what pulmonary fibrosis (PF) researchers face every day —…
The U.S. Food and Drug Administration (FDA) has approved Jascayd (nerandomilast), taken as oral tablets, as a treatment for adults with progressive pulmonary fibrosis (PPF), in which lung scarring worsens over time. “Progressive pulmonary fibrosis is a life-threatening condition with a high unmet medical need. The U.S. approval…
